2019 IN REVIEW DRUG UPDATES AND APPROVALS.
- Resource Type
- Article
- Authors
- Hartsell Crump, Lauren; Benfield, Miranda; Ramey, Caleb; Arcara, Ashley; Yang, Sebin; Brown, Jenna; Mospan, Geoffrey; Mospan, Cortney
- Source
- Nurse Practitioner. Dec2019, Vol. 44 Issue 12, p21-33. 13p.
- Subject
- *ADRENOCORTICAL hormones
*HIV infections
*IMMUNOSUPPRESSIVE agents
*OBSTRUCTIVE lung diseases
*MONOCLONAL antibodies
*MULTIPLE sclerosis
*ORPHAN drugs
*OSTEOPOROSIS
*POSTPARTUM depression
*PSORIASIS
*SLEEP disorders
*DRUG approval
*HIGHLY active antiretroviral therapy
*CONTINUING education units
*MUSCARINIC antagonists
*GABA modulators
*PHARMACODYNAMICS
- Language
- ISSN
- 0361-1817
In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent). [ABSTRACT FROM AUTHOR]